Human prostate cancer model: Roles of growth factors and extracellular matrices
Leland W.K. Chung(VA Palo Alto Health Care System), Andrew C. von Eschenbach(Community Initiatives), Martin Gleave(University of British Columbia), Robert A. Sikes(University of Virginia), Mark Bandyk, Jer‐Tsong Hsieh(The University of Texas Southwestern Medical Center), Wěi Li(Shougang (China)), Haiyen E. Zhau(Cedars-Sinai Medical Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Jeffrey S. Rubin(Paradigm Shift Therapeutics (United States)), Hsi‐Chin Wu(The University of Texas MD Anderson Cancer Center)
Cited by 93
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
American Cancer Society Guidelines for the Early Detection of Cancer
|CA A Cancer Journal for Clinicians|2002|1.6k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k